News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
138,466 Results
Type
Article (4709)
Company Profile (90)
Press Release (133667)
Section
Business (44664)
Career Advice (209)
Deals (6822)
Drug Delivery (13)
Drug Development (18395)
Employer Resources (19)
FDA (1709)
Job Trends (2888)
News (70762)
Policy (4077)
Tag
Academia (302)
Alliances (12645)
Alzheimer's disease (308)
Approvals (1711)
Artificial intelligence (36)
Bankruptcy (38)
Best Places to Work (2336)
Biotechnology (85)
Breast cancer (61)
Cancer (443)
Career advice (196)
CAR-T (45)
Cell therapy (148)
Clinical research (14750)
Collaboration (225)
Compensation (84)
COVID-19 (452)
C-suite (73)
Cystic fibrosis (25)
Data (468)
Diabetes (41)
Diagnostics (789)
Drug discovery (36)
Earnings (12952)
Events (25250)
Executive appointments (216)
FDA (1899)
Funding (185)
Gene therapy (67)
GLP-1 (109)
Government (362)
Healthcare (1777)
Infectious disease (474)
Inflammatory bowel disease (45)
Intellectual property (26)
IPO (3100)
Job creations (695)
Job search strategy (185)
Layoffs (36)
Legal (762)
Lung cancer (30)
Lymphoma (38)
Manufacturing (72)
Medical device (563)
Medtech (563)
Mergers & acquisitions (3884)
Metabolic disorders (96)
Neuroscience (403)
NextGen: Class of 2025 (891)
Non-profit (273)
Northern California (658)
Obesity (50)
Opinion (37)
Parkinson's disease (28)
Patents (41)
People (16811)
Phase I (5777)
Phase II (7004)
Phase III (3705)
Pipeline (208)
Postmarket research (249)
Preclinical (2443)
Press Release (51)
Radiopharmaceuticals (48)
Rare diseases (66)
Real estate (1539)
Regulatory (3216)
Research institute (315)
Series A (32)
Southern California (589)
Startups (1045)
United States (5133)
Vaccines (65)
Date
Last 7 days (147)
Last 30 days (669)
Last 365 days (9327)
2025 (1192)
2024 (9486)
2023 (10278)
2022 (13453)
2021 (13957)
2020 (10817)
2019 (7295)
2018 (5660)
2017 (6599)
2016 (6019)
2015 (7050)
2014 (5393)
2013 (4438)
2012 (4849)
2011 (5270)
2010 (4845)
Location
Africa (138)
Alabama (26)
Asia (8864)
Australia (2104)
California (1501)
Canada (495)
China (90)
Connecticut (55)
Europe (22278)
Florida (139)
Illinois (117)
Indiana (83)
Japan (30)
Maryland (181)
Massachusetts (1109)
Michigan (65)
Minnesota (78)
New Jersey (346)
New York (364)
North Carolina (229)
Northern California (658)
Ohio (32)
Pennsylvania (354)
South America (213)
Southern California (589)
Texas (182)
Washington State (283)
138,466 Results for "immatics biotechnologies gmbh".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
T-CURX GmbH Enters into Technology Access Agreement with Kytopen
February 14, 2025
·
5 min read
Collaboration
BMS’ Cost-Cutting Campaign Claims Collabs With Immatics, Century
Bristol Myers Squibb aims to generate around $1.5 billion in savings through 2025—a goal that it hopes to reach by lowering third-party expenditures, focusing only on key growth brands and cutting some 2,200 jobs by year-end.
December 16, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Immatics Announces Pricing of $150 Million Public Offering
October 11, 2024
·
3 min read
Press Releases
Immatics Announces Proposed $150 Million Public Offering
October 10, 2024
·
3 min read
Business
Immatics Announces First Quarter 2024 Financial Results and Business Update
Immatics N.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, provided a business update and reported financial results for the quarter ended March 31, 2024.
May 14, 2024
·
20 min read
Business
Immatics Announces Full Year 2023 Financial Results and Corporate Update
Immatics N.V. provided a business update and reported financial results for the quarter and full year ended December 31, 2023.
March 21, 2024
·
19 min read
Press Releases
Immatics Appoints Alise Reicin to Board of Directors
July 31, 2024
·
5 min read
Business
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
October 4, 2024
·
3 min read
Lone Star Bio
Immatics Announces Pricing of $175 Million Public Offering
Immatics N.V. announced the pricing of an underwritten public offering of 15,925,000 ordinary shares at a public offering price of $11.00 per share.
January 17, 2024
·
3 min read
Business
Oakwood Chemical Announces Strategic Partnership with EMP Biotech GmbH
Oakwood Chemical is thrilled to unveil its collaboration with EMP Biotech GmbH, a move set to streamline the oligo synthesis supply chain.
April 9, 2024
·
2 min read
1 of 13,847
Next
